3 January, 2026

A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection

2026-01-03T11:22:18+03:00By |Categories: Publications, Therapeutics|Tags: , , |

Christos Psarrakis, Nikolaos-Renatos Tziolos, Vicky Matzarakis, Vinod Kumar, Emmanouil Stylianakis, Chrysanthi Sidiropoulou, Elisavet Tasouli, Konstantina Iliopoulou, Michael Samarkos, Symeon Metallidis, Sarah Georgiadou, Karolina Akinosoglou, Amalia Bolanou, Erifli Hatziagelaki, Alina Kostaki, Periklis Panagopoulos, Konstantinos Toutouzas, Haralarampos Milionis, Georgios Adamis, Garyfallia Poulakou, Malvina Lada, Athanasios Skoutelis, Zoi Alexiou, Styliani Symbardi, George Chrysos, Mihai G. Netea, Evangelos

1 April, 2022

BEYOND

2026-01-03T11:24:03+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: |

Completed study Official Study Title Bezlotoxumab Υielded Οutcomes by addressing personalized Needs in Clostridioides Difficile infection: the BEYOND double-blind randomized clinical trial Brief Description Previous data from our group have shown that integrated information from SNPs of the host DNA, IL-8 and the enrichment of the stool microbiome can indicate the patients with infection

Go to Top